According to a recent LinkedIn post from Tubulis, clinical investigator Prof. Dr. Toon Van Gorp is expected to deliver a rapid oral presentation on Phase I/IIa trial data for lead candidate TUB-040 at the American Society of Clinical Oncology Annual Meeting in Chicago in late May to early June 2026. The presentation is described as part of the “Gynecologic Cancer” session and will focus on updated data from the ongoing dose-escalation portion of the platinum-resistant ovarian cancer cohort.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post notes that the update builds on previously reported clinical activity and safety data presented at ESMO 2025, suggesting a continued development trajectory for TUB-040. For investors, the selection for a rapid oral session at a major oncology conference may indicate scientific and clinical interest in the asset, which could be relevant for assessing the value of Tubulis’ oncology pipeline.
As described in the post, TUB-040 is characterized as a next-generation NaPi2b-targeting antibody-drug conjugate developed with the company’s proprietary Tubutecan linker platform, designed for high stability, optimized targeting and a high drug-to-antibody ratio of eight. If forthcoming data further support efficacy and tolerability in platinum-resistant ovarian cancer, this could strengthen Tubulis’ position in the competitive ADC landscape and potentially enhance its attractiveness for future partnerships or financing.